World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 89 12566 11825 6431 5948 498 33732

Maher Albitar publications per year

The chart shows the history of publications by Maher Albitar between 1989 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Maher Albitar published across 37 years, from 1989 to 2025, averaging 13.9 papers a year. Output peaked at 39 publications in 2009. 22 of the 514 publications appeared in the last two years.

No. of publications
10 20 30
Bar chart. Horizontal axis: year, 1989 to 2025. Vertical axis: number of publications, 0 to 39. Peak 39 publications in 2009. 1989: 2 publications 1990: 0 publications 1991: 2 publications 1992: 5 publications 1993: 2 publications 1994: 2 publications 1995: 3 publications 1996: 6 publications 1997: 12 publications 1998: 2 publications 1999: 17 publications 2000: 24 publications 2001: 22 publications 2002: 34 publications 2003: 34 publications 2004: 30 publications 2005: 33 publications 2006: 29 publications 2007: 26 publications 2008: 15 publications 2009: 39 publications 2010: 22 publications 2011: 15 publications 2012: 4 publications 2013: 1 publication 2014: 8 publications 2015: 6 publications 2016: 15 publications 2017: 20 publications 2018: 18 publications 2019: 5 publications 2020: 3 publications 2021: 1 publication 2022: 4 publications 2023: 31 publications 2024: 7 publications 2025: 15 publications
1989 2025

514 publications in total across all disciplines

View publications per year as a table
Maher Albitar: publications per year, 1989 to 2025
Year Publications
1989 2
1990 0
1991 2
1992 5
1993 2
1994 2
1995 3
1996 6
1997 12
1998 2
1999 17
2000 24
2001 22
2002 34
2003 34
2004 30
2005 33
2006 29
2007 26
2008 15
2009 39
2010 22
2011 15
2012 4
2013 1
2014 8
2015 6
2016 15
2017 20
2018 18
2019 5
2020 3
2021 1
2022 4
2023 31
2024 7
2025 15
Total 514
Download as CSV

Maher Albitar publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Maher Albitar sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 481–500 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 498 publications — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713 498
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Maher Albitar D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Maher Albitar sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 88–89 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 89 D-Index — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970 89
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Maher Albitar is affiliated with the Genomic Testing Cooperative in the United States and has focused their research primarily within the field of medicine, contributing to various subfields including hematology, cancer research, pulmonary and respiratory medicine, genetics, and pathology and forensic medicine.

Their scientific contributions extend to key topics such as acute myeloid leukemia research, lymphoma diagnosis and treatment, cancer genomics and diagnostics, chronic lymphocytic leukemia research, platelet disorders and treatments, myeloproliferative neoplasms diagnosis and treatment, and hematopoietic stem cell transplantation.

Frequent publication venues where Maher Albitar has disseminated their research include:

  • Blood
  • Journal of Clinical Oncology
  • Scandinavian Journal of Urology
  • The American Journal of Gastroenterology
  • Haematologica

Maher Albitar's recent peer-reviewed articles feature studies on prognostic modeling, treatment outcomes, and biomarker research. Selected notable papers include:

  • Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model, 2020, Journal of Clinical Oncology
  • Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome, 2020, Haematologica
  • Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias, 2020, Blood Advances
  • Homologous Recombination Abnormalities Associated With BRCA1/2 Mutations as Predicted by Machine Learning of Targeted Next-Generation Sequencing Data, 2023, Breast Cancer Basic and Clinical Research
  • A prospective study of a urine and plasma biomarker test for the prediction of gleason ≥3 + 4 prostate cancer in a mixed cohort, 2020, Scandinavian Journal of Urology

Collaborative work has involved multiple frequent coauthors, including André Goy, Andrew Ip, Andrew L. Pecora, Ahmad Charifa, and Sally Agersborg.

Best Publications

  • Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

    Hagop Kantarjian;Jean-Pierre J. Issa;Craig S. Rosenfeld M.D.;John M. Bennett

  • Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

    Hagop M Kantarjian;Francis Giles;Lydia Wunderle;Kapil Bhalla

  • Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

    Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien

  • Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

    Michael J. Keating;Susan O'Brien;Maher Albitar;Susan Lerner

  • Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

    Michael J. Keating;Ian Flinn;Vinay Jain;Jacques-Louis Binet

  • Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells.

    Martin Körbling;Ruth L. Katz;Abha Khanna;Arnout C. Ruifrok

  • Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

    Alvaro Aguayo;Hagop M Kantarjian;Taghi Manshouri;Cristi Gidel

  • Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia

    William Wierda;Susan O'Brien;Sijin Wen;Stefan Faderl

  • CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia

    Sherif Ibrahim;Michael Keating;Kim Anh Do;Susan O'Brien

  • Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome

    Christina A. Meyers;Maher Albitar;Elihu Estey

  • Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity

    Elizabeth Oldham Hileman;Jinsong Liu;Maher Albitar;Michael J. Keating

  • Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.

    Alvaro Aguayo;Elihu Estey;Elihu Estey;Hagop M Kantarjian;Hagop M Kantarjian;Taghi Mansouri;Taghi Mansouri

  • B-cell clones as early markers for chronic lymphocytic leukemia.

    Ola Landgren;Maher Albitar;Wanlong Ma;Fatima Abbasi

  • Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

    Francesco Onida;Hagop M. Kantarjian;Terry L. Smith;Greg Ball

  • Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

    David P. Steensma;Maria R. Baer;James L. Slack;Rena Buckstein

  • Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

    Karen W.L. Yee;Zhihong Zeng;Marina Konopleva;Srdan Verstovsek

  • The human MDM-2 oncogene is overexpressed in leukemias.

    Carlos E. Bueso-Ramos;Yun Yang;Elizabeth deLeon;Patrick McCown

  • A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

    Francis Giles;Thomas Fischer;Jorge Cortes;Guillermo Garcia-Manero

  • Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic Leukemia

    Deborah A. Thomas;Jorge Cortes;Susan O'Brien;Sherry Pierce

  • Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.

    Inhye E. Ahn;Chingiz Underbayev;Adam Albitar;Sarah E. M. Herman

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Francis J. Giles
Francis J. Giles Northwestern University
Susan O'Brien
Susan O'Brien University of California, Irvine
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Elihu H. Estey
Elihu H. Estey University of Washington
Mahmoud Aljurf
Mahmoud Aljurf King Faisal Specialist Hospital & Research Centre
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Alessandra Ferrajoli
Alessandra Ferrajoli The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to many related online degrees and career pathways in healthcare. For those interested in health and wellness outside of traditional medicine, an online nutritionist degree can lead to a rewarding career promoting healthy lifestyles and disease prevention.

Advancing into healthcare management is possible through the best online mha programs, which equip students for leadership roles in hospitals and other medical institutions.

Registered nurses seeking to grow their qualifications without interrupting their work can consider the best online rn to bsn programs without clinical requirements, providing flexibility and quicker completion times.

Ambitious nurses aspiring for the highest level of clinical practice might explore a 1 year dnp program online, offering a fast track to leadership and advanced practice.

Each of these programs supports specialized pathways in health professions, helping students tailor their careers to evolving industry demands.

Best Scientists Citing Maher Albitar

Trending Scientists

Recently Published Articles